Post-Market Studies Confirm Sativex Helps in MS Spasticity

BARCELONA -- Multiple sclerosis patients taking the oromucosal cannabis-based spray called Sativex in routine practice to relieve spasticity are getting approximately the same degree of benefit expected from the product's formal trials, according to interim results from two observational studies from Italy reported here.

Modest but statistically significant improvement in spasticity scores (10-point Numerical Rating Scale, NRS) has been seen among 322 patients who added Sativex to standard anti-spasticity drugs and/or physical therapy, according to a group led by Maria Trojano, MD, of the University of Bari, whose ongoing study is called MOVE 2 and who reported data from the first 3 months after enrollment.

A separate study dubbed SA.FE led by Francesco Patti, MD, of the University of Catania, has also yielded similar results during the first few months of therapy, with about 40% of 547 patients showing at least a 30% improvement in NRS scores at 6 months....

Rate this article: 
Region: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.